These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 20602599

  • 1. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing their first treatment cycle of IVF or ICSI.
    Bjercke S, Tanbo T, Abyholm T, Omland A, Opøien HK, Fedorcsak P.
    Acta Obstet Gynecol Scand; 2010 Aug; 89(8):1053-60. PubMed ID: 20602599
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.
    Hompes PG, Broekmans FJ, Hoozemans DA, Schats R, FIRM group.
    Fertil Steril; 2008 Jun; 89(6):1685-93. PubMed ID: 17681325
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial.
    Andersen AN, Devroey P, Arce JC.
    Hum Reprod; 2006 Dec; 21(12):3217-27. PubMed ID: 16873892
    [Abstract] [Full Text] [Related]

  • 4. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H, Huang GN, Cao YX, Zhong Y, Huang YH, Zhu GJ, Zhou LM, Chen ZJ, Shi JZ, Zeng Y, Weng N, Huang XF, Yang J, Zhu YM, Li YP, Yi D, Zhuang GL.
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
    Cheon KW, Byun HK, Yang KM, Song IO, Choi KH, Yoo KJ.
    J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
    [Abstract] [Full Text] [Related]

  • 6. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients.
    Smitz J, Andersen AN, Devroey P, Arce JC, MERIT Group.
    Hum Reprod; 2007 Mar; 22(3):676-87. PubMed ID: 17110397
    [Abstract] [Full Text] [Related]

  • 7. A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count.
    Jayaprakasan K, Hopkisson J, Campbell B, Johnson I, Thornton J, Raine-Fenning N.
    BJOG; 2010 Jun; 117(7):853-62. PubMed ID: 20353458
    [Abstract] [Full Text] [Related]

  • 8. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial.
    Ye H, Huang G, Pei L, Zeng P, Luo X.
    Gynecol Endocrinol; 2012 Jul; 28(7):540-4. PubMed ID: 22390186
    [Abstract] [Full Text] [Related]

  • 9. Results of controlled ovarian stimulation for ART in poor responders according to the short protocol using different gonadotrophins combinations.
    Loutradis D, Elsheikh A, Kallianidis K, Drakakis P, Stefanidis K, Milingos S, Michalas S.
    Arch Gynecol Obstet; 2004 Dec; 270(4):223-6. PubMed ID: 13680266
    [Abstract] [Full Text] [Related]

  • 10. Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF.
    Ziebe S, Lundin K, Janssens R, Helmgaard L, Arce JC, MERIT (Menotrophin vs Recombinant FSH in vitro Fertilisation Trial) Group.
    Hum Reprod; 2007 Sep; 22(9):2404-13. PubMed ID: 17640944
    [Abstract] [Full Text] [Related]

  • 11. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM, Bates GW, Robinson RD, Arthur NJ, Martin JE, Neal GS.
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [Abstract] [Full Text] [Related]

  • 12. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY.
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The influence of gonadotropins on clinico-biological ICSI outcome: a retrospective comparative study rFsH vs HP-hmg.
    Khlifi A, Kacem O, Maroueni M, Elgoul L, Hidar S, Fekih M, Boughizane S, Essaidi H, Ben Regaya L, Bibi M, Ajina M, Khairi H.
    Tunis Med; 2016 Jun; 94(6):167-177. PubMed ID: 28051220
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates.
    Lahoud R, Al-Jefout M, Tyler J, Ryan J, Driscoll G.
    Hum Reprod; 2006 Oct; 21(10):2645-9. PubMed ID: 16785261
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment.
    Andersen AN, Witjes H, Gordon K, Mannaerts B, Xpect investigators.
    Hum Reprod; 2011 Dec; 26(12):3413-23. PubMed ID: 21954280
    [Abstract] [Full Text] [Related]

  • 20. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.
    Moro F, Scarinci E, Palla C, Romani F, Familiari A, Tropea A, Leoncini E, Lanzone A, Apa R.
    Hum Reprod; 2015 Jan; 30(1):179-85. PubMed ID: 25398971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.